




European Federation of Pharmaceutical
Industries and Associations

Cooperation on identification and prioritization of health technologies for joint work



The European Pharmaceutical Industry and Horizon Scanning

- * EFPIA supports healthcare systems in their efforts to better prepare for the introduction of innovative technologies and faster access for patients. Horizon scanning can be an important tool in this respect.
- * Horizon scanning should build on clear principles, transparent processes, and full interaction with all relevant stakeholders, including the industry as the primary provider of information on products pre authorisation.
- * Successful horizon scanning systems, e.g. in Sweden and the UK, build on close collaboration between public authorities and the industry. Continuing dialogue and mutual trust are essential prerequisites for productive horizon scanning.
- * An international mechanism for horizon scanning should strive for reducing duplication through consolidating geography-agnostic data, while national systems are needed to conduct national specific assessments (including impact on health systems, budget impact, local disease burden).

Identification & prioritization of health technologies for joint work

- * **What is the role of horizon scanning / prioritisation** in the future permanent system? Proposal foresees that all centrally authorised products will be assessed
- * During JA3 and in the transition phase, some **prioritisation** is foreseen in order to **support the Coordination Group/ EUnetHTA Executive Board** in the scale up of assessment **capabilities and capacity**
- * Prioritisation needs to be based on **criteria that are unbiased and based on clinical considerations**, eg
 - * unmet medical needs, where there is no treatment or only unsatisfactory treatment available
 - * potential impact on patients and public health, considering, inter alia, the burden of disease measured by mortality and morbidity, and the life-threatening or chronically debilitating nature of the disease targeted by the health technology
 - * significant cross-border dimension
 - * the available resources of the Coordination Group
- * **Prioritisation by the Coordination Group/EUnetHTA Executive Board** needs to be closely linked to a commitment to use the EUnetHTA report
- * **Voluntary submissions** need to be possible
- * **Early dialogue** must remain an option for all centrally approved products

Experience with EPL and considerations moving forward

* EUnetHTA Prioritisation List

- * Importance of transparent and inclusive process at every step of prioritisation
- * Need to plan for validation step with industry before publication

* Implementation considerations – discussion points

* Who?

- * Which stakeholders should be involved in overall process?
- * Companies: who will manage the new process? (R&D, Operations)

* What?


- * Shared data / information needs to be aligned with the purpose (priorities) of the system
- * Confidentiality

* When?

- * Process efficiency
- * Frequency/updates
- * Rate of attrition in clinical development; timing will impact workload
- * Uncertainty over later stage clinical results / impact



European Federation of Pharmaceutical
Industries and Associations



EFPIA Brussels Office
Leopold Plaza Building * Rue du Trône 108
B-1050 Brussels * Belgium
Tel: + 32 (0)2 626 25 55
www.efpia.eu * info@efpia.eu

